English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

GluN2B-NMDA receptors play a key role in several neurological and neurodegenerative disorders. In order to develop novel negative allosteric GluN2B-NMDA receptor modulators, the concept of conformational restriction was pursued, i.e. the flexible aminoethanol substructure of ifenprodil was embedded into a more rigid tetrahydro-3-benzazepine system. The resulting tetrahydro-3-benzazepine-1,7-diol (±)- 2  (WMS-1410) showed promising receptor affinity in receptor binding studies ( K  i  = 84 nM) as well as pharmacological activity in two-electrode-voltage-clamp experiments ( IC  50  = 116 nM) and in cytoprotective assays ( IC  50  = 18.5 nM). The interactions of ( R )- 2  with the ifenprodil binding site of GluN2B-NMDA receptors were analyzed on the molecular level and the “foot-in-the-door” mechanism was developed. Due to promising pharmacokinetic parameters (logD 7.4  = 1.68, plasma protein binding of 76–77%, sufficient metabolic stability) F-substituted analogs were prepared and evaluated as tracers for positron emission tomography (PET). Both fluorine-18-labeled PET tracers [ 18 F] 11  and [ 18 F] 15  showed high brain uptake, specific accumulation in regions known for high GluN2B-NMDA receptor expression, but no interactions with  σ  1  receptors. Radiometabolites were not observed in the brain. Both PET tracers might be suitable for application in humans.

biological chemistry

Chemical, pharmacodynamic and pharmacokinetic characterization of the GluN2B receptor antagonist 3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1 H -3-benzazepine-1,7-diol – starting point for PET tracer development